Table 1.

Clinical characteristics of the study population

Clinical CharacteristicAll PatientsWith 44-h Ambulatory BPMissing 44-h Ambulatory BPP
N15013515
Age (yr) (mean ± SD)55.8 ± 13.556.3 ± 13.051.6 ± 17.30.21
Men94 (63%)88 (65%)6 (40%)0.06
Race0.72
    white13 (9%)11 (8%)2 (13%)
    black135 (90%)122 (90%)13 (87%)
    other2 (1%)2 (1%)0 (0%)
Predialysis weight (kg) (mean ± SD)81.8 ± 19.581.7 ± 19.882.6 ± 17.80.87
Postdialysis weight (kg) (mean ± SD)79.1 ± 19.079.0 ± 19.279.8 ± 17.40.88
Body mass index (kg/m2) (mean ± SD)26.7 ± 6.126.8 ± 6.225.9 ± 6.10.67
Hemodialysis (yr) (mean ± SD)4.0 ± 3.04.0 ± 3.04.1 ± 2.90.85
Etiology of end-stage renal disease0.85
    diabetes mellitus47 (31%)43 (32%)4 (27%)
    hypertension83 (55%)75 (56%)8 (53%)
    glomerulonephritis9 (6%)8 (6%)1 (7%)
    obstruction1 (1%)1 (1%)0 (0%)
    other10 (7%)8 (6%)2 (13%)
Urea reduction ratio (%) (mean ± SD)73.0 ± 7.673.0 ± 7.573.4 ± 8.30.85
Albumin (g/dl) (mean ± SD)3.8 ± 0.43.8 ± 0.43.8 ± 0.40.97
Hemoglobin (g/dl) (mean ± SD)12.4 ± 1.512.5 ± 1.511.9 ± 1.30.13
No. receiving antihypertensive drugs124 (83%)112 (83%)12 (80%)0.77
No. of antihypertensives in users (mean ± SD)2.3 ± 1.22.3 ± 1.21.9 ± 1.10.28
Nature of antihypertensive agent
    dihydropyridine calcium channel blockers49 (33%)45 (33%)4 (27%)0.60
    non-dihydropyridine calcium-channel blockers6 (4%)6 (4%)0 (0%)0.41
    β-blockers94 (63%)85 (63%)9 (60%)0.82
    α-blockers8 (5%)7 (5%)1 (7%)0.81
    centrally acting agents27 (18%)25 (19%)2 (13%)0.62
    vasodilators20 (13%)19 (14%)1 (7%)0.42
    ACE inhibitors57 (38%)52 (39%)5 (33%)0.70
    angiotension receptor blockers22 (15%)21 (16%)1 (7%)0.36
44-h ambulatory BP (mmHg) (mean ± SD)NA130 ± 22.8/73.6 ± 14.2NA
  • BP, blood pressure; ACE, angiotensin converting enzyme; NA, not applicable.